Ai Yoshioka

Ai Yoshioka

Auto-generated profile, based on publicly available information

Ai Yoshioka

Division of Dermatology, Department of Internal Related, Graduate School of Medicine Kobe University Kobe Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
XWXuebing Wang
Xuebing Wang
CCClaire Yik-Lok Chung
Claire Yik-Lok Chung
AYAi Yoshioka
Ai Yoshioka
SHShinya Hashimoto
Shinya Hashimoto
HJHaruki Jimbo
Haruki Jimbo
KNKen-Ichi Noma
Ken-Ichi Noma

1 February 2018 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
AYA Yoshioka
A Yoshioka
SFS Fujiwara
S Fujiwara
HKH Kawano
H Kawano
HNH Nakano
H Nakano
STS Taketani
S Taketani
CNC Nishigori
C Nishigori
Is missing (Short communication)...

1 May 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
NYN. Yamano
N. Yamano
MKM. Kunisada
M. Kunisada
SKS. Kaizu
S. Kaizu
KSK. Sugihara
K. Sugihara
ANA. Nishiaki-Sawada
A. Nishiaki-Sawada
CNC. Nishigori
C. Nishigori

20 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
XWXuebing Wang
Xuebing Wang
CCClaire Yik-Lok Chung
Claire Yik-Lok Chung
AYAi Yoshioka
Ai Yoshioka
SHShinya Hashimoto
Shinya Hashimoto
HJHaruki Jimbo
Haruki Jimbo
KNKen-Ichi Noma
Ken-Ichi Noma
Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, one of the taxanes (genotoxic drugs), although it has a limited effect due to chemoresistance for prolonged treatment. Here we examine a new angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We first find that the chemotherapeutic drugs, cisplatin and paclitaxel, efficiently induce cellular senescence of angiosarcoma cells. Subsequent treatment with a senolytic agent, ABT-263, eliminates senescent cells through the activation of the apoptotic pathway. In addition, expression analysis indicates that senescence-associated secretory phenotype (SASP) genes are activated in senescent angiosarcoma cells and that ABT-263 treatment eliminates senescent cells expressing genes in the type-I interferon (IFN-I) pathway. Moreover, we show that cisplatin treatment alone requires a high dose to remove angiosarcoma cells, whereas a lower dose of cisplatin is sufficient to induce senescence, followed by the elimination of senescent cells by senolytic treatment. This study sheds light on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cisplatin with the ABT-263 senolytic agent, which can help ease the deleterious side effects of chemotherapy.

19 May 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
AYAi Yoshioka
Ai Yoshioka
MKMakoto Kunisada
Makoto Kunisada
HFHitoshi Fukuda
Hitoshi Fukuda
AKAkiharu Kubo
Akiharu Kubo

23 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
XWXuebing Wang
Xuebing Wang
MNMasako Nishida
Masako Nishida
AYAi Yoshioka
Ai Yoshioka
CCClaire Yik-Lok Chung
Claire Yik-Lok Chung
SHShinya Hashimoto
Shinya Hashimoto
TFTakeshi Fukumoto
Takeshi Fukumoto
Xeroderma pigmentosum (XP) is an inherited photoaging syndrome caused by mutations in genes involved in the nucleotide excision repair (NER) pathway. XP patients exhibit hypersensitivity to ultraviolet (UV) radiation, leading to accelerated skin aging and requiring lifelong sun avoidance. Here, we demonstrate that UV-induced DNA damage triggers cellular senescence and up-regulates senescence-associated secretory phenotype (SASP) genes in melanocytes derived from an XP patient. To explore the potential therapeutics for XP, we developed a cisplatin-based drug screening system and identified JAK inhibitors and curcuminoids as promising senomorphic agents. In addition, two classes of senolytic agents, BCL-2-like protein inhibitors and HSP90 inhibitors, effectively eliminate senescent melanocytes. Further analysis demonstrates that senomorphic treatment effectively counteracts senescence and reduces SASP gene expression in XP-derived melanocytes. Moreover, genes in senescence-related pathways, including the JAK/STAT, Type I interferon (IFN-I), and PI3K/AKT pathways, which are activated by both UV irradiation and cisplatin treatment, are down-regulated by senomorphic treatment. This study highlights a potential senotherapeutic strategy for XP, which may help alleviate photoaging symptoms in XP patients.